Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate‐to‐severe psoriasis

Luger, T A; Barker, Jonathan; Lambert, Julien; Yang, Shi-Yi; Robertson, Deborah; Foehl, Joanne; Molta, Charles; Boggs, R.

doi:10.1111/j.1468-3083.2009.03211.x

Cited by 106 publications

(103 citation statements)

References 42 publications

(74 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the same study,patients treated with cyclosporine showed a 37% mean improvement in the NAPSI score (21 (25). The efficacy of etanercept in nail psoriasis has also been supported by other studies (7,26,27).…”

Section: Case Reportsupporting

confidence: 63%

Therapeutic challenges in a case of psoriasis with nail onset

Mitran¹,

Mitran²,

Sârbu³

et al. 2017

J Mind Med Sci.

View full text Add to dashboard Cite

Nail psoriasis affects a large number of patients with psoriasis and has a major psychosocial impact. Furthermore, it may be regarded as a predictor of more severe forms of psoriasis and early sign of psoriatic arthritis. The clinical presentations vary depending on the structure affected (nail matrix or nail bed), the nail lesions may range from minor to severe, but they are not specific. Treatment is a challenge, in most cases the lesions being resistant to therapy. We present a rare case of psoriasis with nail onset in a 59-year-old woman. The nail involvement confined to the fingernails was severe, with significant impairment of the patient's quality of life. Conventional therapies failed to improve the nail lesions, but a marked improvement was achieved under etanercept therapy.Acne conglobata is a rare, severe form of acne vulgaris characterized by the presence of comedones, papules, pustules, nodules and sometimes hematic or meliceric crusts, located on the face, trunk, neck, arms and buttocks. Case ReportWe report the case of a 16 year old Caucasian female patient from the urban area who addressed our Mădălina I. Mitran et al.

show abstract

Section: Case Reportsupporting

confidence: 63%

Therapeutic challenges in a case of psoriasis with nail onset

Mitran¹,

Mitran²,

Sârbu³

et al. 2017

J Mind Med Sci.

View full text Add to dashboard Cite

show abstract

“…Etanercept, a TNF inhibitor, has shown efficacy in nail psoriasis in an open-label, randomised trial (CRYSTEL) including 564 patients with moderate to severe psoriasis with nail involvement receiving etanercept for 54 weeks, either continuously or in a paused treat-to-response fashion [12]. Mean NAPSI scores decreased by 28.9% at 12 weeks (p < 0.001) and continued to decrease by 51% at 54 weeks [12].…”

Section: The Advent Of New Treatment Options With Biologic Therapymentioning

confidence: 99%

“…Nail disease is more common in patients with more severe disease – for example, up to 80% of patients with psoriatic arthritis (PsA) often have nail involvement as part of their condition and, as with psoriasis patients, many rarely receive treatment for nail disease [5,6]. A high association between PsA and nail psoriasis has been noted in several studies [6,7,8,9,10,11,12,13,14]. In fact, a large population-based cohort study of 1,633 psoriasis patients found that psoriasis subjects with nail dystrophy are almost three times more likely to develop PsA than subjects without nail dystrophy [11].…”

Section: Introduction: Difficulty In Treating Psoriasis With Nail Invmentioning

confidence: 99%

Treatment and Management of Psoriasis with Nail Involvement: A Focus on Biologic Therapy

Langley

Daudén

2010

Dermatology

View full text Add to dashboard Cite

Nail involvement in psoriasis is typically overlooked, although it can affect up to 50% of patients with psoriasis and cause functional impact as well as psychological stress that can significantly affect quality of life. In addition, psoriatic patients with nail disease tend to have a more severe skin condition, a higher rate of unremitting and progressive arthritis and more associated anxiety and depression. Historically, the treatment of nail psoriasis has proven difficult, with most patients feeling that the treatment for their nail disease was unsatisfactory. The current management of nail psoriasis includes topical, intralesional and systemic therapies, although little clinical evidence is available on the effectiveness of conventional treatments and, consequently, no specific treatment approach has been fully supported. Biologic agents are beginning to emerge as a viable option to treat patients with both cutaneous and nail clinical manifestations of psoriasis and psoriatic arthritis. The extra disease burden that nail symptoms place on the patient can be considered indicative of a more severe form of the disease and should be taken into consideration when assessing treatment options.

show abstract

“…Kao i u prethodnim studijama [16,19,20], podaci DLQI-a u ovoj studiji pokazuju da ispitanici sa kožnim bolestima imaju najviše skorove na simptomima i osećanjima, što verovatno ukazuje da je doživljaj fizičkog tela centralno pitanje u njihovim životima. Što se tiče visokih skorova za rad ili školovanje iz DLQI-a u ovoj studiji, oni ukazuju da kožna oboljenja nisu samo bolesti koje mogu narušiti fizički izgled pacijenata, već da one umnogome mogu ograničiti njihove aktivnosti na poslu ili školi [1,21,22].…”

Section: Diskusijaunclassified

Agreement between two instruments for measuring quality of life in dermatology

Timotijević-Sojević¹,

Jevtić²,

Ivanovic³

et al. 2014

Praxis Med

View full text Add to dashboard Cite

Instrumenti kvaliteta života specifični za dermatologiju, sve češće se primenjuju u istraživanju kod pacijenata sa kožnim bolestima. CIlj je ispitati odnos ocena kvaliteta života dobijenih primenom dva za dermatologiju specifična instrumenta. Istraživanjem je obuhvaćeno 62 ispitanika sa kožnim bolestima, kod kojih je kvalitet života ocenjen primenom instrumenata specifičnih za dermatologiju (tj. Dermatology Life Quality Index-DLQI i Skindex-16), namenjenih upotrebi kod svih kožnih bolesti. Ukupni skorovi DLQI i Skindex-16 nalazili su se u jakoj korelaciji (r=0.87; p<0.001). Postojale su i statistički značajne korelacije ukupnog skora DLQI sa skorovima za podskale simptomi, emocije i funkcionisanje iz r=0.77 i r=0.86, redom). Ukupan skor Skindex-16 nije bio u korelaciji sa skorom za podskalu tretman iz DLQI-a, međutim, bio je u korelaciji sa skorovima za podskale simptomi i osećanja, dnevne aktivnosti, slobodne aktivnosti, rad ili škola i lični odnosi iz r=0.80, r=0.66, r=0.62 i r=0.68, redom). Dva instrumenta specifična za dermatologiju (npr. DLQI i Skindex-16), ukoliko se zajedno primenjuju, mogu pružiti komplementarne podatke pri ocenjivanju kvaliteta života pacijenata sa kožnim bolestima.Ključne reči: Kožne bolesti, kvalitet života, DLQI, Skindex-16. UVODOboljenja kože u retkim slučajevima ugrožavaju život, međutim, mogu imati nepovoljan uticaj na sve aspekte kvaliteta života, kao što su psihološka dimenzija, fizičko i socijalno funkcionisanje [1,2].Za ocenu kvaliteta života pacijenata sa kožnim bolestima, konstruisano je nekoliko instrumenata specifičnih za dermatologiju, uključujući Skindex-16 i DLQI [3,4,5,6]. Svaki od tih instrumenata sastavljen je od upitnika, sa različitim pitanjima. U istraživanju, instrumenti kvaliteta života specifični za dermatologiju, korišćeni su kod pacijenata sa jednim oboljenjem kože ili uopšte sa kožnim bolestima [7,8,9,10,11,12]. I pored postojanja publikovanih podataka o valjanosti i pouzdanosti za ove instrumente, još uvek ne postoji saglasnost o tome, da li u okviru jedne studije treba koristiti samo jedan ili dva instrumenta za kvalitet života [13,14,15,16]. CILJ RADACilj ove studije bio je da ispita odnos ocena kvaliteta života dobijenih primenom dva za dermatologiju specifična instrumenta (DLQI i Skindex-16). MATERIJAL I METODEStudijska populacija uključivala je ispitanike sa ši-rokim spektrom kožnih bolesti. Svi ispitanici lečeni su na Kožnom odeljenju Zdravstvenog centra u Kosovskoj Mitrovici. Istraživanjem je obuhvaćeno 62 ispitanika. Ispitanici mlađi od 18 godina i ispitanici sa mentalnim i telesnim bolestima nisu uključeni u studiju. Na početku istraživanja, od ispitanika su prikupljani podaci o sociodemografskim varijablama, kao što su pol, starosno doba, socijalni status. Prilikom pregleda, kod svih ispitanika, dijagnozu kožnog oboljenja postavio je dermatolog, zatim, ispitanici su sami, u prisustvu dermatologa popunili instrumente kvaliteta života specifične za dermatologiju: Skindex-16 i DLQI. 6] se sastoji od upitnika sa 16 pitanja, o tome u kom stepenu kožn...

show abstract

Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate‐to‐severe psoriasis

Abstract: In this study of moderate-to-severe plaque psoriasis, joint and nail symptoms were prevalent and patients with these symptoms had significantly greater HR-QoL impairment at baseline than unaffected patients. Etanercept provided significant improvement in symptom severity and HR-QoL.

Cited by 106 publications

References 42 publications

Therapeutic challenges in a case of psoriasis with nail onset

Therapeutic challenges in a case of psoriasis with nail onset

Treatment and Management of Psoriasis with Nail Involvement: A Focus on Biologic Therapy

Agreement between two instruments for measuring quality of life in dermatology

Contact Info

Product

Resources

About